DURECT concludes patient enrolment in Phase IIb trial of AH therapy
DURECT has concluded enrolment of patients in the Phase IIb clinical trial of larsucosterol for the treatment of severe alcohol-associated …
Emergex reports positive outcomes from naNO-DENGUE Phase I trial
Emergex Vaccines has reported positive outcomes from the naNO-DENGUE Phase I trial of DengueTcP, a T cell-priming immune set-point candidate …
VALUE-Dx initiative to tackle antimicrobial resistance in respiratory infections
World Antimicrobial Awareness Week (WAAW) is a global campaign held annually in November to improve awareness and understanding of antimicrobial …
Baudax Bio reports promising additional data for neuromuscular blockade agent
Baudax Bio revealed additional results from a Phase II trial investigating its neuromuscular blockade (NMD) agent BX1000 in patients undergoing …
Systemic sclerosis: understanding gender differences of a complex disease
Systemic sclerosis (SSc), also known as scleroderma, is a complex autoimmune disease that affects the skin and various organs in …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
FibroGen’s study of DMD therapy fails to meet primary endpoint
FibroGen’s Phase III LELANTOS-1 clinical study of pamrevlumab has failed to meet the primary endpoint of Performance of the Upper …
CIRM awards grant to support Eureka’s T-cell therapy trial
The California Institute for Regenerative Medicine (CIRM) has awarded a $10.6m grant to support Eureka Therapeutics’ ARYA-2 Phase I clinical …
Cellf Bio’s first-in-human implantation of BioSphincter
Cellf Bio has reported the first human implantation of its autologous bioengineered sphincter BioSphincter in a Phase I clinical trial …
Arbutus previews Hepatitis B RNAi treatment data
Arbutus is gearing up to present preliminary safety and antiviral activity of AB-729 combination treatment in virally suppressed, HBeAg-negative subjects …
Oncternal doses first patient in trial of B cell lymphoma therapy
Oncternal Therapeutics has dosed the first patient in its Phase I/II trial of ONCT-808, a ROR1 targeting autologous CAR T …
LianBio reports positive topline data from gastric cancer therapy trial
LianBio has reported positive topline results from a Phase IIa trial of infigratinib for the treatment of locally advanced or …
QurAlis receives authorisation to initiate ALS therapy trial in EU
QurAlis has received clinical trial authorisation (CTA) in the European Union (EU) to initiate a first-in-human, Phase I ANQUR clinical …
BPGbio doses first patients in Phase II GBM therapy trial
BPGbio has dosed the first patients in a Phase II clinical trial of BPM 31510 to treat Glioblastoma Multiforme (GBM), …
ASCO 2023: blockbuster Enhertu demonstrates efficacy across multiple tumour types
At the American Society of Clinical Oncology (ASCO) Annual Meeting, 2-6 June 2023, interim results were presented for the Phase …
FDA open for feedback on GCP draft guidance
The US Food and Drug Administration (FDA) released a draft guidance with updated recommendations for good clinical practices (GCPs). The draft …